Search

Your search keyword '"Nagai, Koji"' showing total 357 results
Start Over Author "Nagai, Koji"
357 results on '"Nagai, Koji"'

1. Association of large joint involvement at the start of biological disease‐modifying antirheumatic drugs and Janus kinase inhibitors with disease activity and drug retention in patients with rheumatoid arthritis: The ANSWER cohort study

Author

Shirasugi, Iku, primary, Onishi, Akira, additional, Nishimura, Keisuke, additional, Yamamoto, Wataru, additional, Murakami, Kosaku, additional, Onizawa, Hideo, additional, Maeda, Yuichi, additional, Ebina, Kosuke, additional, Son, Yonsu, additional, Amuro, Hideki, additional, Katayama, Masaki, additional, Hara, Ryota, additional, Nagai, Koji, additional, Hiramatsu, Yuri, additional, Hashimoto, Motomu, additional, Okano, Tadashi, additional, Maeda, Toshihisa, additional, Hayashi, Shinya, additional, Sendo, Sho, additional, Jinno, Sadao, additional, Yamamoto, Yuzuru, additional, Yamada, Hirotaka, additional, Ueda, Yo, additional, and Saegusa, Jun, additional

Published
2024
Full Text
View/download PDF

3. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study-

Author

Ebina, Kosuke, Hirano, Toru, Maeda, Yuichi, Yamamoto, Wataru, Hashimoto, Motomu, Murata, Koichi, Takeuchi, Tohru, Nagai, Koji, Son, Yonsu, Amuro, Hideki, Onishi, Akira, Jinno, Sadao, Hara, Ryota, Katayama, Masaki, Yamamoto, Keiichi, Kumanogoh, Atsushi, and Hirao, Makoto

Published
2020
Full Text
View/download PDF

4. The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study

Author

Murata, Koichi, Hashimoto, Motomu, Yamamoto, Wataru, Son, Yonsu, Amuro, Hideki, Nagai, Koji, Takeuchi, Tohru, Katayama, Masaki, Maeda, Yuichi, Ebina, Kosuke, Hara, Ryota, Jinno, Sadao, Onishi, Akira, Murakami, Kosaku, Tanaka, Masao, Ito, Hiromu, Mimori, Tsuneyo, and Matsuda, Shuichi

Published
2020
Full Text
View/download PDF

5. Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study

Author

Ebina, Kosuke, primary, Etani, Yuki, additional, Maeda, Yuichi, additional, Okita, Yasutaka, additional, Hirao, Makoto, additional, Yamamoto, Wataru, additional, Hashimoto, Motomu, additional, Murata, Koichi, additional, Hara, Ryota, additional, Nagai, Koji, additional, Hiramatsu, Yuri, additional, Son, Yonsu, additional, Amuro, Hideki, additional, Fujii, Takayuki, additional, Okano, Takaichi, additional, Ueda, Yo, additional, Katayama, Masaki, additional, Okano, Tadashi, additional, Tachibana, Shotaro, additional, Hayashi, Shinya, additional, Kumanogoh, Atsushi, additional, Okada, Seiji, additional, and Nakata, Ken, additional

Published
2023
Full Text
View/download PDF

7. Prognostic Factors Affecting Death in Patients with Rheumatoid Arthritis Complicated by Pneumocystis jirovecii Pneumonia and One-Year Clinical Course: The ANSWER Cohort Study

Author

Shiba, Hideyuki, primary, Kotani, Takuya, additional, Nagai, Koji, additional, Hata, Kenichiro, additional, Yamamoto, Wataru, additional, Yoshikawa, Ayaka, additional, Wada, Yumiko, additional, Hiramatsu, Yuri, additional, Makino, Hidehiko, additional, Ueda, Yo, additional, Onishi, Akira, additional, Murata, Koichi, additional, Amuro, Hideki, additional, Son, Yonsu, additional, Hara, Ryota, additional, Hirano, Toru, additional, Ebina, Kosuke, additional, Katayama, Masaki, additional, Hashimoto, Motomu, additional, and Takeuchi, Tohru, additional

Published
2023
Full Text
View/download PDF

9. Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study

Author

Ebina, Kosuke, Hashimoto, Motomu, Yamamoto, Wataru, Hirano, Toru, Hara, Ryota, Katayama, Masaki, Onishi, Akira, Nagai, Koji, Son, Yonsu, Amuro, Hideki, Yamamoto, Keiichi, Maeda, Yuichi, Murata, Koichi, Jinno, Sadao, Takeuchi, Tohru, Hirao, Makoto, Kumanogoh, Atsushi, and Yoshikawa, Hideki

Published
2019
Full Text
View/download PDF

11. Prognostic factors affecting respiratory-related death in patients with rheumatoid arthritis complicated by interstitial lung disease: An ANSWER cohort study.

Author

Hidehiko Makino, Kotani, Takuya, Hata, Kenichiro, Nishioka, Daisuke, Yamamoto, Wataru, Yoshikawa, Ayaka, Wada, Yumiko, Hiramatsu, Yuri, Shiba, Hideyuki, Nagai, Koji, Katayama, Masaki, Yonsu Son, Amuro, Hideki, Onishi, Akira, Akashi, Kengo, Hara, Ryota, Hirano, Toru, Hashimotoj, Motomu, and Takeuchia, Tohru

Subjects
INTERSTITIAL lung diseases, RHEUMATOID arthritis, PROGNOSIS, COHORT analysis, DISEASE duration, PEPTIDES
Abstract

The aim of this multi-centre retrospective study was to clarify the prognostic factors for respiratory-related death in patients with interstitial lung disease (ILD) complicated rheumatoid arthritis (RA). Patient background data, treatment regimen, and disease activity indicators of RA and ILD at baseline, 6 months after the diagnosis of ILD, and at the last follow-up visit were extracted. A total of 312 patients with RA-ILD (17 patients who died from respiratory-related causes and 295 survivors) were included. Patients who died from respiratory-related causes had an older median age, a higher proportion of being male, and a higher anti-cyclic citrullinated peptide antibody positivity rate than survivors (p =.0001, .038, and .016, respectively); they also had significantly higher baseline serum levels of Krebs von den Lungen-6 (KL-6) than survivors (p =.013). Patients who died from respiratory-related causes showed significantly greater changes in serum KL-6 levels between the 6-month time point and the last visit [ΔKL-6 (6 months - last)] than survivors (p =.011). Multivariate analysis showed that the ΔKL-6 (6 months - last) corrected by disease duration was a predictor of respiratory-disease-related death in patients with RA-ILD (p < .0001). Long-term increase in serum KL-6 levels is associated with respiratory-disease related death in patients with RA-ILD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

13. Prognostic factors affecting respiratory-related death in patients with rheumatoid arthritis complicated by interstitial lung disease: An ANSWER cohort study

Author

Makino, Hidehiko, primary, Kotani, Takuya, additional, Hata, Kenichiro, additional, Nishioka, Daisuke, additional, Yamamoto, Wataru, additional, Yoshikawa, Ayaka, additional, Wada, Yumiko, additional, Hiramatsu, Yuri, additional, Shiba, Hideyuki, additional, Nagai, Koji, additional, Katayama, Masaki, additional, Son, Yonsu, additional, Amuro, Hideki, additional, Onishi, Akira, additional, Akashi, Kengo, additional, Hara, Ryota, additional, Hirano, Toru, additional, Hashimoto, Motomu, additional, and Takeuchi, Tohru, additional

Published
2022
Full Text
View/download PDF

14. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study

Author

Hashimoto, Motomu, Furu, Moritoshi, Yamamoto, Wararu, Fujimura, Takanori, Hara, Ryota, Katayama, Masaki, Ohnishi, Akira, Akashi, Kengo, Yoshida, Shuzo, Nagai, Koji, Son, Yonsu, Amuro, Hideki, Hirano, Toru, Ebina, Kosuke, Uozumi, Ryuji, Ito, Hiromu, Tanaka, Masao, Ohmura, Koichiro, Fujii, Takao, and Mimori, Tsuneyo

Published
2018
Full Text
View/download PDF

18. The Association of Disease Activity and Estimated GFR in Patients With Rheumatoid Arthritis: Findings From the ANSWER Study

Author

Onishi, Akira, primary, Akashi, Kengo, additional, Yamamoto, Wataru, additional, Ebina, Kosuke, additional, Murata, Koichi, additional, Hara, Ryota, additional, Katayama, Masaki, additional, Nagai, Koji, additional, Hirano, Toru, additional, Amuro, Hideki, additional, Son, Yonsu, additional, Yamamoto, Keiichi, additional, Hashimoto, Motomu, additional, and Morinobu, Akio, additional

Published
2021
Full Text
View/download PDF

19. The real-world effectiveness of anti-RANKL antibody denosumab on the clinical fracture prevention in patients with rheumatoid arthritis: The ANSWER cohort study

Author

Murata, Koichi, primary, Uozumi, Ryuji, additional, Hashimoto, Motomu, additional, Ebina, Kosuke, additional, Akashi, Kengo, additional, Onishi, Akira, additional, Nagai, Koji, additional, Yoshikawa, Ayaka, additional, Katayama, Masaki, additional, Son, Yonsu, additional, Amuro, Hideki, additional, Hara, Ryota, additional, Yamamoto, Wataru, additional, Watanabe, Ryu, additional, Murakami, Kosaku, additional, Tanaka, Masao, additional, Ito, Hiromu, additional, Morinobu, Akio, additional, and Matsuda, Shuichi, additional

Published
2021
Full Text
View/download PDF

25. The family history of rheumatoid arthritis in anti-cyclic citrullinated peptide antibody-positive patient is not a predictor of poor clinical presentation and treatment response with modern classification criteria and treatment strategy: the ANSWER cohort study

Author

Murata, Koichi, primary, Hashimoto, Motomu, additional, Yamamoto, Wataru, additional, Son, Yonsu, additional, Amuro, Hideki, additional, Nagai, Koji, additional, Takeuchi, Tohru, additional, Katayama, Masaki, additional, Maeda, Yuichi, additional, Ebina, Kosuke, additional, Hara, Ryota, additional, Jinno, Sadao, additional, Onishi, Akira, additional, Murakami, Kosaku, additional, Tanaka, Masao, additional, Ito, Hiromu, additional, Mimori, Tsuneyo, additional, and Matsuda, Shuichi, additional

Published
2019
Full Text
View/download PDF

26. Multiple velocity measurements of grid turbulence interacted with a spherical shock wave

Author

Inokuma, Kento, Watanabe, Tomoaki, Nagai, Koji, and Sakai, Yasuhiko

Subjects
Shock Wave, Wind Tunnel, Grid Turbulence, Shock Tube
Abstract

平成30年度衝撃波シンポジウム (2019年3月5日-7日. 横浜国立大学経済・経営学部講義棟1号館 ）横浜市, 神奈川県, Symposium on Shock Waves in Japan, FY2018 (March 5-7, 2019. Yokohama National University), Yokohama, Kanagawa, 資料番号: SA6000134008, レポート番号: 1A2-2 [若]

Published
2019

32. Additional file 1: of Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study

Author

Motomu Hashimoto, Moritoshi Furu, Wararu Yamamoto, Fujimura, Takanori, Hara, Ryota, Katayama, Masaki, Ohnishi, Akira, Akashi, Kengo, Yoshida, Shuzo, Nagai, Koji, Yonsu Son, Amuro, Hideki, Hirano, Toru, Ebina, Kosuke, Uozumi, Ryuji, Hiromu Ito, Tanaka, Masao, Ohmura, Koichiro, Fujii, Takao, and Tsuneyo Mimori

Subjects
musculoskeletal diseases, skin and connective tissue diseases
Abstract

Figure S1. Kaplanâ Meier survival curve for maintaining bDMARD-free remission after discontinuation of each bDMARD. X axis represents days after bDMARD discontinuation. Y axis represents rates of maintained BFR. bDMARD biological disease-modifying anti-rheumatic drug, BFR biological disease-modifying anti-rheumatic drug-free remission, ABT abatacept, ADA adalimumab, CZP certolizumab, ETN etanercept, GLM golimumab, IFX infliximab, TCZ tocilizumab (PDF 80Â kb) (PDF 79 kb)

Published
2018
Full Text
View/download PDF

33. Additional file 3: of Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study

Author

Motomu Hashimoto, Moritoshi Furu, Wararu Yamamoto, Fujimura, Takanori, Hara, Ryota, Katayama, Masaki, Ohnishi, Akira, Akashi, Kengo, Yoshida, Shuzo, Nagai, Koji, Yonsu Son, Amuro, Hideki, Hirano, Toru, Ebina, Kosuke, Uozumi, Ryuji, Hiromu Ito, Tanaka, Masao, Ohmura, Koichiro, Fujii, Takao, and Tsuneyo Mimori

Subjects
musculoskeletal diseases
Abstract

Table S1. Types of bDMARDs and hazard ratios for bDMARD-free remission failure in bDMARD-naïve patients (univariate analysis). bDMARD-naïve patients classified into four groups based on types of bDMARDs. Hazard ratios with 95% CIs obtained using Cox’s proportional hazard model. CI confidence interval, bDMARD biological disease-modifying antirheumatic drug, TNFi(mAb) monoclonal antibodies against TNF (infliximab, adalimumab, and golimumab), TNFi(R/P) soluble TNF receptor or Fab fragments against TNF fused with polyethylene glycol (etanercept and certolizumab), CTLA4-Ig abatacept, IL-6Ri interleukin-6 receptor inhibitor (tocilizumab) (DOCX 15 kb) (DOCX 15 kb)

Published
2018
Full Text
View/download PDF

34. Additional file 2: of Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study

Author

Motomu Hashimoto, Moritoshi Furu, Wararu Yamamoto, Fujimura, Takanori, Hara, Ryota, Katayama, Masaki, Ohnishi, Akira, Akashi, Kengo, Yoshida, Shuzo, Nagai, Koji, Yonsu Son, Amuro, Hideki, Hirano, Toru, Ebina, Kosuke, Uozumi, Ryuji, Hiromu Ito, Tanaka, Masao, Ohmura, Koichiro, Fujii, Takao, and Tsuneyo Mimori

Subjects
musculoskeletal diseases
Abstract

Figure S2. Kaplan–Meier survival curve for maintaining bDMARD-free remission after discontinuation of different types of bDMARDs in bDMARD-naïve patients. bDMARD-naïve patients classified into four groups based on types of bDMARDs. Kaplan–Meier method used to estimate BFR maintenance time. bDMARD biological disease-modifying anti-rheumatic drug, BFR biological disease-modifying anti-rheumatic drug-free remission, TNFi(mAb) monoclonal antibodies against TNF (infliximab, adalimumab, and golimumab), TNFi(R/P) soluble TNF receptor or Fab fragments against TNF fused with polyethylene glycol (etanercept and certolizumab), CTLA4-Ig abatacept, IL-6Ri interleukin-6 receptor inhibitor (tocilizumab), CI confidence interval (PDF 80 kb) (PDF 79 kb)

Published
2018
Full Text
View/download PDF

35. Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis-interstitial lung disease

Author

Matsuda, Shogo, primary, Kotani, Takuya, additional, Ishida, Takaaki, additional, Fukui, Keisuke, additional, Fujiki, Youhei, additional, Suzuka, Takayasu, additional, Nagai, Koji, additional, Hata, Kenichiro, additional, Shoda, Takeshi, additional, Isoda, Kentaro, additional, Ito, Yuri, additional, Makino, Shigeki, additional, Takeuchi, Tohru, additional, and Arawaka, Shigeki, additional

Published
2019
Full Text
View/download PDF

36. SAT0287 SERUM CYTOKINE PROFILE IDENTIFIES PATHOMECHANISM AND EFFICIENT BIOMARKERS OF DISEASE ACTIVITY AND PROGNOSIS IN INTERSTITIAL PNEUMONIA COMBINED WITH POLYMYOSITIS/DERMATOMYOSITIS

Author

Matsuda, Shogo, primary, Kotani, Takuya, additional, Ishida, Takaaki, additional, Fujiki, Youhei, additional, Suzuka, Takayasu, additional, Nagai, Koji, additional, Hata, Kenichiro, additional, Shoda, Takeshi, additional, Isoda, Kentaro, additional, Makino, Shigeki, additional, Takeuchi, Tohru, additional, and Arawaka, Shigeki, additional

Published
2019
Full Text
View/download PDF

38. Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study-

Author

Ebina, Kosuke, primary, Hashimoto, Motomu, additional, Yamamoto, Wataru, additional, Hirano, Toru, additional, Hara, Ryota, additional, Katayama, Masaki, additional, Onishi, Akira, additional, Nagai, Koji, additional, Son, Yonsu, additional, Amuro, Hideki, additional, Yamamoto, Keiichi, additional, Maeda, Yuichi, additional, Murata, Koichi, additional, Jinno, Sadao, additional, Takeuchi, Tohru, additional, Hirao, Makoto, additional, Kumanogoh, Atsushi, additional, and Yoshikawa, Hideki, additional

Published
2019
Full Text
View/download PDF

42. Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis-interstitial lung disease.

Author

Matsuda, Shogo, Kotani, Takuya, Ishida, Takaaki, Fukui, Keisuke, Fujiki, Youhei, Suzuka, Takayasu, Nagai, Koji, Hata, Kenichiro, Shoda, Takeshi, Isoda, Kentaro, Ito, Yuri, Makino, Shigeki, Takeuchi, Tohru, and Arawaka, Shigeki

Subjects
BIOMARKERS, CLASSIFICATION, CLUSTER analysis (Statistics), CYTOKINES, DEATH, DERMATOMYOSITIS, FACTOR analysis, FERRITIN, INTERSTITIAL lung diseases, MACROPHAGES, MONOCYTES, NEUTROPHILS, OXYGEN, PATIENTS, POLYMYOSITIS, PULMONARY gas exchange, T cells, DESCRIPTIVE statistics
Abstract

Objectives To elucidate the serum cytokine profile and address the pathomechanism of interstitial lung disease (ILD) complicated with PM/DM. Methods Forty patients with PM/DM-ILD were enrolled, and principal components analysis and cluster analysis were performed to classify patients into subgroups. Additionally, we compared cytokine profiles between the survivors and dead patients and between anti-melanoma differentiation-associated gene 5 antibody- and anti-aminoacyl tRNA synthetase antibody-positive ILD patients. We also examined the association of various cytokines with disease activity indicators and prognosis of ILD. Results The principal components analysis data allowed classification of the cytokine profile into three groups: group 1, neutrophilic and M1-macrophage-driven cytokines; group 2, type 1 Th cell-driven and M2-macrophage-induced cytokines; and group 3, M2-macrophage-driven cytokines. Cluster analysis showed the presence of PM/DM-ILD patient groups with high or low levels of total cytokines. Ninety percent of patients who died of ILD were included in clusters with high cytokine levels. Serum cytokine levels of all groups were significantly higher in the anti-melanoma differentiation-associated gene 5 antibody-positive patients than in the anti-aminoacyl tRNA synthetase antibody-positive patients. Groups 1 and 2 significantly correlated with known factors for poor prognosis, such as serum ferritin levels and alveolar-arterial oxygen difference. Serum cytokine levels of patients in group 1 were significantly higher initially and at 2 and 4 weeks in those who died. Conclusion These findings suggested that the activation of monocytes, macrophages and type 1 Th cells, and neutrophils play roles in the pathomechanism of PM/DM-ILD, and group 1 cytokines could be useful biomarkers for predicting prognosis of PM/DM-ILD. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

45. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study-

Author

Ebina, Kosuke, primary, Hashimoto, Motomu, additional, Yamamoto, Wataru, additional, Ohnishi, Akira, additional, Kabata, Daijiro, additional, Hirano, Toru, additional, Hara, Ryota, additional, Katayama, Masaki, additional, Yoshida, Shuzo, additional, Nagai, Koji, additional, Son, Yonsu, additional, Amuro, Hideki, additional, Akashi, Kengo, additional, Fujimura, Takanori, additional, Hirao, Makoto, additional, Yamamoto, Keiichi, additional, Shintani, Ayumi, additional, Kumanogoh, Atsushi, additional, and Yoshikawa, Hideki, additional

Published
2018
Full Text
View/download PDF

46. Efficacy and safety of combination therapy with prednisolone and oral tacrolimus for progressive interstitial pneumonia with systemic sclerosis: A retrospective study

Author

Konma, Junichi, primary, Kotani, Takuya, additional, Shoda, Takeshi, additional, Suzuka, Takayasu, additional, Fujiki, Youhei, additional, Nagai, Koji, additional, Hata, Kenichiro, additional, Yoshida, Shuzo, additional, Takeuchi, Tohru, additional, Makino, Shigeki, additional, and Arawaka, Shigeki, additional

Published
2018
Full Text
View/download PDF

47. Efficacy of abatacept tapering therapy for sustained remission in patients with rheumatoid arthritis: Prospective single‐center study.

Author

Yoshida, Shuzo, Kotani, Takuya, Kimura, Yuko, Matsumura, Yoko, Yoshikawa, Ayaka, Tokai, Nao, Ozaki, Takuro, Nagai, Koji, Takeuchi, Toru, Makino, Shigeki, and Arawaka, Shigeki

Subjects
RHEUMATOID arthritis, LONGITUDINAL method, DISEASE duration, BIOLOGICAL laboratories, C-reactive protein
Abstract

Aim: To investigate whether remission can be sustained for rheumatoid arthritis (RA) patients after tapering abatacept (ABT). Method: All patients were naïve to biological disease‐modifying anti‐rheumatic drugs (bDMARDs) and in low or moderate Disease Activity Score of 28 joints with C‐reactive protein (DAS)28‐CRP). ABT was administrated intravenously (IV) or subcutaneously (SC) for 36 weeks to patients with RA, who had not previously received bDMARDs. As the ABT tapering protocol, ABT was administrated SC at 125 mg every 2 weeks for 12 weeks in patients with remission. RA disease activity was assessed by DAS28‐CRP and ultrasonography. Remission was assessed by defining it as DAS28‐CRP <2.3. Results: Of the 51 patients, 84.3% were women (mean age 68.7 ± 10.2 years, mean disease duration 7.7 ± 10.2 years). Twenty‐nine patients achieved remission and a power Doppler (PD) score ≤1 at each joint at 36 weeks, followed by tapering ABT. Of these patients, 25 sustained DAS28‐CRP remission, and DAS28‐CRP was not significantly elevated (1.62 ± 0.41 to 1.69 ± 0.49) at 48 weeks, but the total PD score was significantly elevated (1.52 ± 1.21 to 2.59 ± 2.81 P = 0.049). Longer disease duration, higher DAS28‐CRP at 24 weeks, and higher total PD score at 24 weeks were predictors of an elevated total PD score after tapering ABT therapy. Conclusion: These findings suggest that ABT tapering is a promising short‐term strategy to sustain remission in patients with RA, and ultrasonography is a useful tool for monitoring disease activity after tapering ABT. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results